Dallas, TX -- (SBWire) -- 12/07/2010 -- ReportsnReports announce Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition
http://www.reportsnreports.com/reports/33665-emerging-cancer-vaccines-forecasts-developments-and-pipeline-an.html
Original Source : Emerging Cancer Vaccines Market
http://www.reportsnreports.com/reports/33665-emerging-cancer-vaccines-forecasts-developments-and-pipeline-an.html
Buy Now : Market Research
http://www.reportsnreports.com/
Browse complete Report at : Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition
http://www.reportsnreports.com/reports/33665-emerging-cancer-vaccines-forecasts-developments-and-pipeline-an.html
Kalorama has been researching and examining the development of cancer vaccines for seven years. In April 2010, the cancer vaccine market experienced one of the biggest achievements in the therapeutic vaccine treatment of cancer—the approval of the prostate cancer vaccine PROVENGE (TM). This, in addition to the success of cervical cancer vaccine products, has created a viable market for what was merely a speculative area just one decade ago.
Even with achievements for some companies, numerous vaccines with apparently strong prospects have been hit by developmental delays and failures. These include CancerVax's Canvaxin, Aphton's Insegia, Progenics' GMK vaccine, and Biomira's Theratope. Despite setbacks many developers are hopeful of a turnaround.
With a couple prophylactic vaccines for cervical cancer on the market, a few select therapeutic vaccine approvals and several therapeutic vaccines on a promising path to commercialization, the market could see a surge of regulatory activity and an influx of market opportunities.
This Kalorama Information report - Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis - focuses on both preventive and therapeutic cancer vaccines in development. The following cancers for which there are vaccines in development or where there is a potential are profiled:
Cervical
Colon/Rectal
Lung
Lymphoma
Melanoma
Prostate
Breast
Gastrointestinal
Renal
Brain
Bladder
Ovarian
Leukemia
The report includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there is current vaccines development are profiled. Each market segment provides an overview, descriptions of products available or in development, market estimates and forecasts for 2010-2015, and competitive analysis of leading developers for 2015.
The report also includes current issues and trends affecting the industry.
This area of medicine is a new frontier and many of the issues that face the cancer vaccine market are novel. However, this is a very promising area of medicine, which will continue to assist in the fight against cancer.
Issues and trends discussed in The Emerging Cancer Vaccine Market include:
Early Detection and Screening
Monoclonal Antibodies and Therapeutic Vaccines
Safety Concerns
Insurance and Reimbursement Issues
Personalized Medicine
Pharmacogenomics
Vaccine Strategies
Economic Conditions and Vaccine Discovery
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information.
For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and development representatives.
All market data pertains to the world market at the manufacturers’ level. The years outlined in this study include projected markets for 2010 thru 2015. Compound annual growth rates (CAGRs) are provided for the 2010-2015 for each vaccine segment covered. Competitive analysis is provided for the year 2015 for the developing and emerging market. The projected competitive analysis for 2015 was based on products in late stage development, probability of approval and marketing, and demographic trends.
Several companies have promising research and development activities for cancer vaccines. Additionally, many companies are in early stage development with a focused effort on providing favorable results in treating cancer. Many of these companies are:
Accentia
Antigenics
AVAX
Dendreon
GlaxoSmithKline
Merck & Co.
Northwest Biotherapeutics
Oncothyreon
Vaccinogen
TABLE OF CONTENTS
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Disease Burden
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors
CHAPTER TWO: INTRODUCTION
Introduction
Cancer Descriptions
Timeline of Cancer Vaccine Developments
History and Growth of the Cancer Treatment Market
Types of Vaccines
Antigen/Adjuvant Vaccines
Whole Cell Tumor Vaccines
Dendritic Cell (DC) Vaccines
Viral Vectors and DNA Vaccines
Idiotype Vaccines
Types of Therapeutic Vaccines
Patient-Specific Vaccines
Prostate Specific Antigen
Sialyl Tn
Heat Shock Proteins
Ganglioside Molecules
Carcinoembryonic Antigen (CEA)
MART-1
Tyrosinase
Adjuvants
Industry Structure
Demographics and Statistics
Growing and Aging Population
Tobacco Use and Obesity Increases Cancer Risk
Tobacco Use
Obesity
Life Expectancy and Cancer
CHAPTER THREE: CERVICAL CANCER VACCINES
Overview
Description of Vaccines on the Market
Gardasil/Silgard
Cervarix
Description of Vaccines in Development
V503
RG3484
PV701
Lovaxin C
VGX-3100
CA-9
Market Summary
Current and Potential Competitors and Analysis, 2015
CHAPTER FOUR: COLON/RECTAL CANCER VACCINES
Overview
Description of Vaccines on the Market
OncoVAX
Description of Vaccines in Development
OncoVAX
TroVAX
CEA VRP Vaccine (AVX701)
IMA910
CDX-1307
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
MKC1106-PP
GI-4000
GVAX
Oncophage
CRS-207
Lapuleucel-T
Market Summary
Potential Competitors and Analysis, 2015]
CHAPTER FIVE: LUNG CANCER VACCINES
Overview
Description of Vaccines in Development
Lucanix
MAGE-A3 Peptide
Stimuvax
EGF Cancer Vaccine
HyperAcute Lung
GI-4000
Oncophage
TG 4010
LungVAX
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
DCVax-Lung
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER SIX: LYMPHOMA VACCINES
Overview
Description of Vaccines in Development
BiovaxID
MyVax
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER SEVEN: MELANOMA VACCINES
Overview
Description of Vaccines on the Market
Description of Vaccines in Development
MVAX
Allovectin-7
MDX-1379 with Combination Treatment MDX-010
Oncophage
MAGE-A3 ASCI
ALVAC Vaccine
HyperAcute Melanoma
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER EIGHT: PROSTATE CANCER VACCINES
Overview
Description of Vaccines on the Market
Provenge
Description of Vaccines in Development
DCVax-Prostate
GVAX
PROSTVAC-VF
TroVAX
Onyvax-P
MVA-BN Prostate
HyperAcute Prostate
NeuVax
MKC1106-PP
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER NINE: BREAST CANCER VACCINES
Overview
Description of Vaccines in Development
Stimuvax
NeuVax
GVAX
AVX701 Vaccine
MVA-BN HER2
Lapuleucel-T
CDX-1307-02
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
MKC1106-PP
Market Summary
ABBREVIATIONS
Browse all : Healthcare
http://www.reportsnreports.com/market-research/healthcare/
Browse all : Kalorama Information
http://www.reportsnreports.com/publishers/kalorama-information/
Browse all : Newly Published
http://www.reportsnreports.com/LatestReport.aspx
Related Reports :
Cancer Vaccines - Pipeline Analysis and Market Forecasts to 2016
http://www.reportsnreports.com/reports/15798-cancer-vaccines-pipeline-analysis-and-market-forecasts-to-2016.html
Worldwide Market for Cancer Diagnostics, 4th Edition, The
http://www.reportsnreports.com/reports/19691-worldwide-market-for-cancer-diagnostics-4th-edition-the.html
Meningitis Preventive Vaccines - Pipeline Analysis and Market Forecasts to 2017
http://www.reportsnreports.com/reports/37183-meningitis-preventive-vaccines-pipeline-analysis-and-market-for.html
Influenza Vaccines - Pipeline Analysis and Market Forecasts to 2016
http://www.reportsnreports.com/reports/15799-influenza-vaccines-pipeline-analysis-and-market-forecasts-to-20.html
Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015
http://www.reportsnreports.com/reports/15778-hepatitis-b-vaccines-pipeline-analysis-and-market-forecasts-to-.html
About ReportsnReports
ReportsnReports is comprising of an online library of 50,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites.
Our client list boasts of almost all well-known publishers of such reports across the globe. We, as a third party reseller of market research reports employ number of marketing tools such as press releases, email-marketing and effective search engine optimization technique to drive revenues for our clients.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsnreports.com/
Blog: http://reportsnreports.wordpress.com/
Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsnReports